Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, comments on the recent approval of teclistamab in triple-class exposed patients with relapsed/refractory (R/R) multiple myeloma by the European Commission. This approval will allow patients who were not eligible for treatment with CAR-Ts and antibody-drug conjugates (ADC) to have an alternative treatment option. In clinical trials, teclistamab has been shown to have an overall response rate (ORR) of 60% and a manageable safety profile. Nevertheless, as teclistamab treatment has been associated with infections, it is necessary to prescribe adequate prophylaxis. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.